ClinicalTrials.gg
CompletedNCT03541200Updated Jan 23, 2026Results posted

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

A Phase 2 interventional study of MT-8554 in Vasomotor Symptoms (VMS), sponsored by Tanabe Pharma America, Inc.. Completed at 53 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01

02

Conditions studied

  • Vasomotor Symptoms (VMS)
03

In context

Lead sponsor

Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed to participate in this study.
  • Subjects who complete the preceding trial (Study MT-8554-A01) through Week 12.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet the withdrawal criteria for the proceeding trial (Study MT-8554-A01)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Open Label

    MT-8554

    Drug: MT-8554

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Adverse Events

    Time frame: 52 Weeks

  2. Percentage of Subjects With Serious Adverse Events

    Time frame: 52 Weeks

  3. Percentage of Subjects With Clinical Laboratory Tests Abnormalities

    Hematology, biochemistry, coagulation and urinalysis

    Time frame: 52 Weeks

  4. Change in Blood Pressure

    Systolic and diastolic blood pressure

    Time frame: Baseline and 52 Weeks

  5. Change in Heart Rate

    Time frame: Baseline and 52 Weeks

  6. Change in ECG Parameters

    PR, QRS, QT and QTc

    Time frame: Baseline and 52 Weeks

  7. Change in Endometrial Thickness as Measured by Transvaginal Ultrasound

    Time frame: Baseline and 52 Weeks

  8. Percentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy

    Time frame: 52 Weeks

Secondary outcomes

  1. Change in Average Daily Frequency of Moderate to Severe VMS

    Subjects were asked to record frequency and severity of VMS in an electronic diary. Severity levels are defined as follows. Mild : Sensation of heat without sweating Moderate : Sensation of heat with sweating, able to continue activity Severe : Sensation of heat with sweating, causing cessation of activity

    Time frame: Baseline and 52 Weeks

  2. Change in Average Daily Severity Score of Mild to Severe VMS

    Baseline VMS severity score : (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) VMS severity score for a specific week during the open label treatment period :(1xFmi+2xFmo+3xFse)/(Fmi+Fmo+Fse) Fmi, Fmo, and Fse are the daily frequencies of mild, moderate, and severe VMS respectively. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity).

    Time frame: Baseline and 52 Weeks

07

Results

Posted Oct 3, 2022

Participant flow

Participant flow — Overall Study
MilestoneMT-8554
Started190
Completed77
Not completed113
Withdrew: Adverse event19
Withdrew: Death1
Withdrew: Lost to follow-up10
Withdrew: Physician decision1
Withdrew: Protocol violation51
Withdrew: Withdrawal by subject23
Withdrew: Other8

Outcome measures

PrimaryPercentage of Subjects With Adverse Events
Time frame:
52 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects With Adverse Events
percentage of subjectsMT-8554
Percentage of Subjects With Adverse Events56.7
PrimaryPercentage of Subjects With Serious Adverse Events
Time frame:
52 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects With Serious Adverse Events
percentage of subjectsMT-8554
Percentage of Subjects With Serious Adverse Events3.2
PrimaryPercentage of Subjects With Clinical Laboratory Tests Abnormalities

Hematology, biochemistry, coagulation and urinalysis

Time frame:
52 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects With Clinical Laboratory Tests Abnormalities
percentage of subjectsMT-8554
Percentage of Subjects With Clinical Laboratory Tests Abnormalities15.5
PrimaryChange in Blood Pressure

Systolic and diastolic blood pressure

Time frame:
Baseline and 52 Weeks
Reported as:
Mean · mmHg
Change in Blood Pressure
mmHgMT-8554
Systolic Blood Pressure1.3 ± 11.36
Diastolic Blood Pressure-0.4 ± 7.65
PrimaryChange in Heart Rate
Time frame:
Baseline and 52 Weeks
Reported as:
Mean · beats/min
Change in Heart Rate
beats/minMT-8554
Change in Heart Rate2.6 ± 7.96
PrimaryChange in ECG Parameters

PR, QRS, QT and QTc

Time frame:
Baseline and 52 Weeks
Reported as:
Mean · msec
Change in ECG Parameters
msecMT-8554
PR0.4 ± 16.34
QRS-0.2 ± 9.46
QT-6.8 ± 22.86
QTcF-0.6 ± 18.60
QTcB1.2 ± 19.66
PrimaryChange in Endometrial Thickness as Measured by Transvaginal Ultrasound
Time frame:
Baseline and 52 Weeks
Reported as:
Mean · mm
Change in Endometrial Thickness as Measured by Transvaginal Ultrasound
mmMT-8554
Change in Endometrial Thickness as Measured by Transvaginal Ultrasound-0.138 ± 1.4765
PrimaryPercentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy
Time frame:
52 Weeks
Reported as:
Number · percentage of subjects
Percentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy
percentage of subjectsMT-8554
Percentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy0
SecondaryChange in Average Daily Frequency of Moderate to Severe VMS

Subjects were asked to record frequency and severity of VMS in an electronic diary. Severity levels are defined as follows. Mild : Sensation of heat without sweating Moderate : Sensation of heat with sweating, able to continue activity Severe : Sensation of heat with sweating, causing cessation of activity

Time frame:
Baseline and 52 Weeks
Reported as:
Mean · episodes/day
Change in Average Daily Frequency of Moderate to Severe VMS
episodes/dayMT-8554
Change in Average Daily Frequency of Moderate to Severe VMS-2.71 ± 4.974
SecondaryChange in Average Daily Severity Score of Mild to Severe VMS

Baseline VMS severity score : (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) VMS severity score for a specific week during the open label treatment period :(1xFmi+2xFmo+3xFse)/(Fmi+Fmo+Fse) Fmi, Fmo, and Fse are the daily frequencies of mild, moderate, and severe VMS respectively. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity).

Time frame:
Baseline and 52 Weeks
Reported as:
Mean · units on a scale
Change in Average Daily Severity Score of Mild to Severe VMS
units on a scaleMT-8554
Change in Average Daily Severity Score of Mild to Severe VMS-0.325 ± 0.6804

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-85541/187 (0.5%)6/187 (3.2%)91/187 (48.7%)
Most frequent serious events
Most frequent serious events
EventMT-8554
DiverticulitisInfections and infestations1/187
Road traffic accidentInjury, poisoning and procedural complications1/187
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/187
Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/187
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/187
CystoceleReproductive system and breast disorders1/187
RectoceleReproductive system and breast disorders1/187
Vaginal prolapseReproductive system and breast disorders1/187
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/187
Most frequent other events
Showing 10 of 53
Most frequent other events
EventMT-8554
Paraesthesia oralGastrointestinal disorders14/187
ParaesthesiaNervous system disorders14/187
Upper respiratory tract infectionInfections and infestations10/187
Feeling hotGeneral disorders9/187
HypoaesthesiaNervous system disorders8/187
Urinary tract infectionInfections and infestations7/187
Back painMusculoskeletal and connective tissue disorders6/187
Hypoaesthesia oralGastrointestinal disorders5/187
OverdoseInjury, poisoning and procedural complications5/187
Alanine aminotransferase increasedInvestigations5/187

Baseline characteristics

3 subjects did not take any study medication so these subjects were excluded from the Safety Population.

Age, Continuous
Age, Continuous(years)MT-8554
Mean54.6 ± 6.66
Sex: Female, Male
Sex: Female, Male(Participants)MT-8554
Female187
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MT-8554
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American47
White138
More than one race0
Unknown or Not Reported1
08

Study locations

53 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Dothan, Alabama 36303, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    Norwalk, California 90650, United States
  • Research Site
    Sacramento, California 94203, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Denver, Colorado 80209, United States
  • Research Site
    New London, Connecticut 33176, United States
  • Research Site
    Clearwater, Florida 33759, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    Fort Myers, Florida 33900, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Jupiter, Florida 33458, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Miami, Florida 33185, United States
  • Research Site
    Orlando, Florida 32801, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Port Saint Lucie, Florida 34952, United States
  • Research Site
    Sarasota, Florida 34231, United States
  • Research Site
    Wellington, Florida 33414, United States
  • Research Site
    West Palm Beach, Florida 33409, United States
  • Research Site
    Sandy Springs, Georgia 30328, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Hutchinson, Kansas 67501, United States
  • Research Site
    Wichita, Kansas 67226, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Metairie, Louisiana 70001, United States
  • Research Site
    Baltimore, Maryland 21208, United States
  • Research Site
    Kalamazoo, Michigan 49009, United States
  • Research Site
    Saginaw, Michigan 48504, United States
  • Research Site
    Kansas City, Missouri 64114, United States
  • Research Site
    Missoula, Montana 59801, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Lawrenceville, New Jersey 08648, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cleveland, Ohio 44101, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Columbus, Ohio 43231, United States
  • Research Site
    Englewood, Ohio 45322, United States
  • Research Site
    Philadelphia, Pennsylvania 19114, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Schertz, Texas 78154, United States
  • Research Site
    Draper, Utah 84020, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Seattle, Washington 98101, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Nov 2019, 18 months.

Results were first posted in Oct 2022, 2 years 10 months after primary completion. A results delay was requested in Nov 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
May 30, 2018
StartActual
Apr 18, 2018
Primary completionActual
Nov 15, 2019
CompletionActual
Nov 15, 2019
Results delay requested
Nov 10, 2020
Results first posted
Oct 3, 2022
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03541200
Responsible party
Sponsor
First posted
May 30, 2018
Start date
Apr 18, 2018
Primary completion
Nov 15, 2019
Completion
Nov 15, 2019
Results posted
Oct 3, 2022
Last update
Jan 23, 2026

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion